ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. operates as an early-stage biopharmaceutical company which develops and commercializes novel cancer immunotherapeutic products. It focus on the adaptive immune system and are often confronted with limited clinical benefits due to low response rates and inevitable drug resistance and/or relapse in many cancer indications. The company was founded by Dr. Tian Wenzhi in June 2015 and is headquartered in Zhangjiang Science City, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company